Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Insulin for Remission in Newly Diagnosed T2D
NCT00494988Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2004
- Primary completion
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin aspart and neutral protamine hagedorn in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Remission rate at 24 weeks. Started Dec 2004; status: completed.
02
Drugs
insulin aspartneutral protamine hagedorn
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00494988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494988.